Funds and ETFs AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe 06:20:11 2024-02-26 am EST 5-day change 1st Jan Change
10,263 GBX +0.42% Intraday chart for AstraZeneca PLC -1.36% -3.06%

ETFs positioned on AstraZeneca PLC

Name Weight AuM 1st Jan change Investor Rating
9.20% 11 M€ +0.83% -
5.39% 190 M€ +5.92%
5.17% 19 M€ +4.62% -
4.89% 725 M€ +1.49%
4.11% 88 M€ +10.37% -
3.47% 206 M€ +1.61%
2.74% 4 M€ -.--% -
2.57% 6 M€ -.--%
2.53% 4 M€ +6.34% -
2.53% 1,380 M€ +1.60%
1.54% 29 M€ +8.37% -
1.51% 2 M€ +9.19% -
1.51% 2 M€ -.--% -
1.26% 12 M€ +15.09% -
1.19% 50 M€ +3.85%
1.16% 10 M€ -3.35% -
0.97% 7 M€ +0.68% -
0.89% 31 M€ +3.32% -
0.86% 276 M€ +11.40% -
0.70% 312 M€ -.--% -
0.69% 197 M€ +6.56% -
0.69% 639 M€ +8.09%
0.57% 205 M€ -.--%
0.54% 284 M€ -.--%
0.51% 786 M€ -.--%
0.51% 23 M€ -.--% -
0.50% 206 M€ -.--%
0.48% 656 M€ +5.69%
0.43% 280 M€ +11.50%
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (3.1%). Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
129.5 USD
Average target price
161.8 USD
Spread / Average Target
+24.89%
Consensus
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW